Logotipo del repositorio
Logotipo del repositorio
 

A narrative review and expert panel recommendations on dyslipidaemia management after acute coronary syndrome in countries outside western Europe and North America

Vista sencilla de ítem
dc.contributor.authorReda, Ashraf
dc.contributor.authorAlmahmeed, Wael
dc.contributor.authorIdit, Dobrecky-Mery
dc.contributor.authorPo-Hsun, Huang
dc.contributor.authorJuarez-Herrera, Ursulo
dc.contributor.authorRanjith, Naresh
dc.contributor.authorSayre, Tobias
dc.contributor.authorUrina-Triana, Miguel
dc.date.accessioned2020-04-02T21:15:06Z
dc.date.available2020-04-02T21:15:06Z
dc.date.issued2020-02-12
dc.description.abstractPatients who have experienced an acute coronary syndrome (ACS) are at very high risk of recurrent atherosclerotic cardiovascular disease (CVD) events. Dyslipidaemia, a major risk factor for CVD, is poorly controlled post ACS in countries outside Western Europe and North America, despite the availability of effective lipid-modifying therapies (LMTs) and guidelines governing their use. Recent guideline updates recommend that low-density lipoprotein cholesterol (LDL-C), the primary target for dyslipidaemia therapy, be reduced by C 50% and to \1.4 mmol/L (55 mg/dL) in patients at very high risk of CVD, including those with ACS. The high prevalence of CVD risk factors in some regions outside Western Europe and North America confers a higher risk of CVD on patients in these countries. ACS onset is often earlier in these patients, and they may be more challenging to treat. Other barriers to effective dyslipidaemia control include low awareness of the value of intensive lipid lowering in patients with ACS, physician non-adherence to guideline recommendations, and lack of efficacy of currently used LMTs. Lack of appropriate pathways to guide follow-up of patients with ACS post discharge and poor access to intensive medications are important factors limiting dyslipidaemia therapy in many countries. Opportunities exist to improve attainment of LDL-C targets by the use of country-specific treatment algorithms to promote adherence to guideline recommendations, medical education and greater prioritisation by healthcare systems of dyslipidaemia management in very high risk patients.en
dc.format.mimetypepdfspa
dc.identifier.doihttps://doi.org/10.1007/s12325-020-01302-4
dc.identifier.issn0741238X
dc.identifier.urihttps://hdl.handle.net/20.500.12442/5084
dc.language.isoengen
dc.publisherSpringeren
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.accessrightsinfo:eu-repo/semantics/closedAccessen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceAdvances in Therapyen
dc.sourceVol. 37, N° 2 Año (2020)spa
dc.subjectAtherosclerosisen
dc.subjectAcute coronary syndromeen
dc.subjectDyslipidaemiaen
dc.subjectLDL-Cen
dc.subjectPCSK9 inhibitoren
dc.subjectStatinen
dc.titleA narrative review and expert panel recommendations on dyslipidaemia management after acute coronary syndrome in countries outside western Europe and North Americaen
dc.typearticleen
dc.type.driverarticleen
dcterms.referencesGrundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73:3168–209.en
dcterms.referencesMach F, Baigent C, Catapano AL, et al. 2019 ESC/ EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–88.en
dcterms.referencesPearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy andachieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459–67.en
dcterms.referencesWaters DD, Brotons C, Chiang CW, et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation. 2009;120:28–34.en
dcterms.referencesReiner Z, De Backer G, Fras Z, et al. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries—findings from the EUROASPIRE IV survey. Atherosclerosis. 2016;246: 243–50.en
dcterms.referencesKotseva K, De Bacquer D, Jennings C, et al. Time trends in lifestyle, risk factor control, and use of evidence-based medications in patients with coronary heart disease in Europe: results from 3 EUROASPIRE surveys, 1999–2013. Glob Heart. 2017;12(315–22):e3.en
dcterms.referencesDanchin N, Almahmeed W, Al-Rasadi K, et al. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: the international cholesterol management practice study (ICLPS). Eur J Prev Cardiol. 2018;25:1087–94.en
dcterms.referencesGitt AK, Lautsch D, Ferrieres J, et al. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: results from the dyslipidemia international study II. Atherosclerosis. 2017;266:158–66.en
dcterms.referencesGrundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73:e285–350.en
dcterms.referencesJellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23:1–87.en
dcterms.referencesLi YH, Ueng KC, Jeng JS, et al. 2017 Taiwan lipid guidelines for high risk patients. J Formos Med Assoc. 2017;116:217–48.en
dcterms.referencesHu DY. New guidelines and evidence for prevention and treatment of dyslipidemia and atherosclerotic cardiovascular disease in China. Chronic Dis Transl Med. 2017;3:73–4.en
dcterms.referencesCatapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37:2999–3058.en
dcterms.referencesCannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–97.en
dcterms.referencesSchwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097–107.en
dcterms.referencesSabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376: 1713–22.en
dcterms.referencesColombian Society of Cardiology. Clinical pathway for the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients over 13 years of age. 2017. http://www.scc.org.co/certificaciones/ imagenes/Guia-clinica-21-noviembre-2017.pdf. Accessed 23 Aug 2019.en
dcterms.referencesYamac¸ AH, Kilic¸ U. Effect of statins on sirtuin 1 and endothelial nitric oxide synthase expression in young patients with a history of premature myocardial infarction. Turk Kardiyol Dern Ars. 2018;46:205–15.en
dcterms.referencesYusufali AM, AlMahmeed W, Tabatabai S, Rao K, Binbrek A. Acute coronary syndrome registry from four large centres in United Arab Emirates (UAEACS Registry). Heart Asia. 2010;2:118–21.en
dcterms.referencesIqbal F, Barkataki JC. Spectrum of acute coronary syndrome in North Eastern India—a study from a major center. Indian Heart J. 2016;68:128–31.en
dcterms.referencesSingh A, Singh V, Ranjan R. Survey of assessment and management of coronary heart disease patients (SMART) in India. J Assoc Physicians India. 2017;65: 22–6.en
dcterms.referencesWang R, Neuenschwander FC, Lima Filho A, et al. Use of evidence-based interventions in acute coronary syndrome—subanalysis of the ACCEPT registry. Arq Bras Cardiol. 2014;102:319–26.en
dcterms.referencesMoustaghfir A, Haddak M, Mechmeche R. Management of acute coronary syndromes in Maghreb countries: the ACCESS (ACute Coronary Events—a multinational Survey of current management Strategies) registry. Arch Cardiovasc Dis. 2012;105: 566–77.en
dcterms.referencesZubaid M, Rashed WA, Almahmeed W, et al. Management and outcomes of Middle Eastern patients admitted with acute coronary syndromes in the Gulf Registry of Acute Coronary Events (Gulf RACE). Acta Cardiol. 2009;64:439–46.en
dcterms.referencesChen KC, Yin WH, Wu CC, et al. In-hospital implementation of evidence-based medications is associated with improved survival in diabetic patients with acute coronary syndrome—data from TSOC ACS-DM Registry. Acta Cardiol Sin. 2018;34: 211–23.en
dcterms.referencesShyu KG, Wu CJ, Mar GY, et al. Clinical characteristics, management and in-hospital outcomes of patients with acute coronary syndrome—observations from the Taiwan ACS full spectrum registry. Acta Cardiol Sin. 2011;27:135–44.en
dcterms.referencesAlhabib KF, Hersi A, Alfaleh H, et al. Baseline characteristics, management practices, and in-hospital outcomes of patients with acute coronary syndromes: results of the Saudi project for assessment of coronary events (SPACE) registry. J Saudi Heart Assoc. 2011;23:233–9.en
dcterms.referencesYan BPY, Chan CKY, Tse G, et al. How to bridge residual distance to target LDL-C in acute coronary syndrome after initial statin therapy? Eur Heart J. 2017;38:P3681.en
dcterms.referencesGuntekin U, Tosun V, Kilinc AY, et al. ST segment elevation myocardial infarction (STEMI) patients are more likely to achieve lipid-lowering treatment goals: a retrospective analysis of patients presenting with first acute coronary syndromes. Medicine. 2018;97:e12225.en
dcterms.referencesJiang J, Zhou YJ, Li JJ, et al. Uncontrolled hyperlipidemia in Chinese patients who experienced acute coronary syndrome: an observational study. Ther Clin Risk Manag. 2018;14:2255–64.en
dcterms.referencesDai YY, Zhang HS, Zhang XG, et al. Statin-ezetimibe versus statin lipid-lowering therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention. J Thorac Dis. 2017;9: 1345–52en
dcterms.referencesLi L, Zhang M, Su F, et al. Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes. Lipids Health Dis. 2015;14:10.en
dcterms.referencesAuckle R, Su B, Li H, et al. Familial hypercholesterolemia in Chinese patients with premature STsegment-elevation myocardial infarction: prevalence, lipid management and 1-year follow-up. PLoS One. 2017;12:e0186815.en
dcterms.referencesAl-Rasadi K, Al-Zakwani I, Alsheikh-Ali AA, et al. Prevalence, management, and outcomes of familial hypercholesterolemia in patients with acute coronary syndromes in the Arabian Gulf. J Clin Lipidol. 2018;12(685–92):e2.en
dcterms.referencesWang WT, Hellkamp A, Doll JA, et al. Lipid testing and statin dosing after acute myocardial infarction. J Am Heart Assoc. 2018;7:460. https://doi.org/10. 1161/jaha.117.en
dcterms.referencesBurgess S, Ference BA, Staley JR, et al. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis. JAMA Cardiol. 2018;3:619–27.en
dcterms.referencesO’Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139:1483–92.en
dcterms.referencesRay KK, Corral P, Morales E, Nicholls SJ. Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options. Lancet. 2019;394:697–708.en
dcterms.referencesSchmidt AF, Swerdlow DI, Holmes MV, et al. PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol. 2017;5:97–105.en
dcterms.referencesBae KH, Kim SW, Choi YK, et al. Serum levels of PCSK9 are associated with coronary angiographic severity in patients with acute coronary syndrome. Diabetes Metab J. 2018;42:207–14.en
dcterms.referencesDalgic Y, Abaci O, Kocas C, et al. The relationship between protein convertase subtilisin kexin type-9 levels and extent of coronary artery disease in patients with non-ST-elevation myocardial infarction. Coron Artery Dis. 2020;31:81–6.en
dcterms.referencesKoskinas KC, Windecker S, Pedrazzini G, et al. Evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS). J Am Coll Cardiol. 2019;74:2452–62.en
dcterms.referencesBlom DJ, Almahmeed W, Al-Rasadi K, et al. Lowdensity lipoprotein cholesterol goal achievement in patients with familial hyphercholesterolemia in countries outside Western Europe: the international cholesterol managament practice study. J Clin Lipidol. 2019;13:594–600.en
dcterms.referencesPijlman AH, Huijgen R, Verhagen SN, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large crosssectional study in the Netherlands. Atherosclerosis. 2010;209:189–94.en
dcterms.referencesMathews R, Wang TY, Honeycutt E, et al. Persistance with secondary prevention medications after acute myocardial infarction: insights from the TRANSLATE-ACS study. Am Heart J. 2015;170:62–9.en
dcterms.referencesYan BP, Chan CK, Tse G, et al. Projected efficacy of statin mono- and combination therapy based on distance from baseline to target LDL-C level in acute coronary syndrome. Value Health. 2018;21:S26.en
dcterms.referencesReda A, Ashraf M, Soliman M, et al. The pattern of risk-factor profile in Egyptian patients with acute coronary syndrome: phase II of the Egyptian cross sectional cardiorisk project. Cardiovasc J Afr. 2019;30:87–94.en
dcterms.referencesJuarez-Herrera U, Jerjes-Sanchez C, Renasica II Investigators. Risk factors, therapeutic approaches, and in-hospital outcomes in Mexicans with ST-elevation acute myocardial infarction: the RENASICA II multicenter registry. Clin Cardiol. 2013;36:241–8.en
dcterms.referencesYusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–52en
dcterms.referencesRoth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70:1–25.en
dcterms.referencesEAS Familial Hypercholesterolaemia Studies Collaboration, Vallejo-Vaz AJ, De Marco M, et al. Overview of the current status of familial hypercholesterolaemia care in over 60 countries—the EAS familial hypercholesterolaemia studies collaboration (FHSC). Atherosclerosis. 2018;277:234–55.en
dcterms.referencesRanjith N, Pegoraro RJ, Zaah MG. Risk factors associated with acute coronary syndromes in South African Adian Indian patients (the AIR study). J Clin Exp Cardiol. 2011;2:1000163.
dcterms.referencesGehani AA, Al-Hinai AT, Zubaid M, et al. Association of risk factors with acute myocardial infarction in Middle Eastern countries: the INTERHEART Middle East study. Eur J Prev Cardiol. 2014;21: 400–10.en
dcterms.referencesWu Y, Li S, Patel A, et al. Effect of a quality of care improvement initiative in patients with acute coronary syndrome in resource-constrained hospitals in China: a randomized clinical trial. JAMA Cardiol. 2019;4:418–27.en
dcterms.referencesLee CK, Lai CL, Lee MH, et al. Reinforcement of patient education improved physicians’ adherence to guideline-recommended medical therapy after acute coronary syndrome. PLoS One. 2019;14: e0217444.en
dcterms.referencesAl-Sayed N, Al-Waili K, Alawadi F, et al. Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East. Int J Cardiol. 2016;225:268–83.en
dcterms.referencesAlshamiri M, Ghanaim MMA, Barter P, et al. Expert opinion on the applicability of dyslipidemia guidelines in Asia and the Middle East. Int J Gen Med. 2018;11:313–22.en
dcterms.referencesThe Egyptian Cardiology Task Force Board members. The Egyptian consensus of dyslipidaemia Adv Ther management. 2017. http://www.mohealth.gov.eg/ UserFiles/LibraryFiles/295396.pdf. Accessed 10 Dec 2019.en
dcterms.referencesKlug E, Raal FJ, Marais AD, et al. South African dyslipidaemia guideline consensus statement: 2018 update. A joint statement from the South African Heart Association (SA Heart) and the Lipid and Atherosclerosis Society of Southern Africa (LASSA). S Afr Med J. 2018;108:973–1000.en
dcterms.referencesLopez MJ, Morales PK, Fontes LRD, et al. Guı´a de tratamiento farmacolo´gico de dislipidemias para el primer nivel de atencio´n. Rev Mex Cardiol. 2013;24: 103–29.en
dcterms.referencesCarvalho LS, Martins NV, Moura FA, et al. Highdensity lipoprotein levels are strongly associated with the recovery rate of insulin sensitivity during the acute phase of myocardial infarction: a study by euglycemic hyperinsulinemic clamp. J Clin Lipidol. 2013;7:24–8.en
dcterms.referencesAtkins ER, Du X, Wu Y, et al. Use of cardiovascular prevention treatments after acute coronary syndrome in China and associated factors. Int J Cardiol. 2017;241:444–9.en
dcterms.referencesSobhy M, El Etriby A, El Nashar A, et al. Prevalence of lipid abnormalities and cholesterol target value attainment in Egyptian patients presenting with an acute coronary syndrome. Egypt Heart J. 2018;70: 129–34.en
dcterms.referencesGitt AK, Lautsch D, Ferrie`res J, et al. Contemporary data on treatment practices for low-density lipoprotein cholesterol in 3867 patients who had suffered an acute coronary syndrome across the world. Data Brief. 2017;16:369–75.en
dcterms.referencesLee VW, Chau RY, Cheung HY, et al. How low should we target the LDL goal to improve survival for acute coronary syndrome patients in Hong Kong? BMC Cardiovasc Disord. 2015;15:117.en
dcterms.referencesYan BPY, Chan CKY, Tse G, et al. A paradox of under-treatment of acute coronary syndrome patients with low baseline LDL-C\1.8 mmol/L. Eur Heart J. 2017;38:P3679.en
dcterms.referencesLee VW, Wang Y, Wu J, et al. The impact of lowdensity lipoprotein cholesterol goal attainments on cardiovascular outcomes: a retrospective cohort study in chinese acute coronary syndrome patients. Value Health. 2017;20:A262.en
dcterms.referencesYan BP, Chiang FT, Ambegaonkar B, et al. Lowdensity lipoprotein cholesterol target achievement in patients surviving an acute coronary syndrome in Hong Kong and Taiwan—findings from the dyslipidemia international study II. Int J Cardiol. 2018;265:1–5.en
dcterms.referencesJaywant SV, Singh AK, Prabhu MS, Ranjan R. Statin therapy/lipid lowering therapy among Indian adults with first acute coronary event: the dyslipidemia residual and mixed abnormalities IN spite of statin therapy (REMAINS) study. Indian Heart J. 2016;68:646–54.en
dcterms.referencesPatel JP, Parikh KH, Patel JC, et al. Diabetes and management of lipid level following PCI in acute coronary syndrome patients. Int J Pharm Res. 2010;2:13–20.en
dcterms.referencesKlempfner R, Goldenberg I, Fisman EZ, et al. Comparison of statin alone versus bezafibrate and statin combination in patients with diabetes mellitus and acute coronary syndrome. Am J Cardiol. 2014;113: 12–6.en
dcterms.referencesOzaydın M, Tu¨rker Y, Erdog˘an D, et al. Effect of previous statin use on the incidence of sustained ventricular tachycardia and ventricular fibrillation in patients presenting with acute coronary syndrome. Anadolu Kardiyol Derg. 2011;11:22–8.en
dcterms.referencesde Matos Soeiro A, de Barros ESPG, Roque EA, et al. Mortality reduction with use of oral beta-blockers in patients with acute coronary syndrome. Clinics (Sao Paulo). 2016;71:635–8.en
dcterms.referencesFilgueiras Filho NM, Feitosa Filho GS, Solla DJF, et al. Implementation of a regional network for STsegment-elevation myocardial infarction (STEMI) care and 30-day mortality in a low- to middle-income city in Brazil: findings from Salvador’s STEMI Registry (RESISST). J Am Heart Assoc. 2018;7:14.en
dcterms.referencesGaedke M, Costa JS, Manenti ER, et al. Use of medicines recommended for secondary prevention of acute coronary syndrome. Rev Saude Publica. 2015. https://doi.org/10.1590/s0034-8910. 2015049005978.en
dcterms.referencesMaier Gde S, Martins EA. Health care for patients with acute coronary syndrome according to quality indicators. Rev Bras Enferm. 2016;69:757–64.en
dcterms.referencesNicolau JC, Franken M, Lotufo PA, et al. Use of demonstrably effective therapies in the treatment of acute coronary syndromes: comparison between different Brazilian regions. Analysis of the Brazilian Registry on Acute Coronary Syndromes (BRACE). Arq Bras Cardiol. 2012;98:282–9.en
dcterms.referencesPiegas LS, Avezum A, Guimaraes HP, et al. Acute coronary syndrome behavior: results of a Brazilian registry. Arq Bras Cardiol. 2013;100:502–10.en
dcterms.referencesSantos ES, Baltar VT, Pereira MP, et al. Comparison between cardiac troponin I and CK-MB mass in acute coronary syndrome without ST elevation. Arq Bras Cardiol. 2011;96:179–87.en
dcterms.referencesSoeiro AM, Arau´jo VA, Vella JP, et al. Is there any relationship between TSH levels and prognosis in acute coronary syndrome? Arq Bras Cardiol. 2018;110:113–8.en
dcterms.referencesTodo MC, Bergamasco CM, Azevedo PS, et al. Impact of coronary intensive care unit in treatment of myocardial infarction. Rev Assoc Med Bras. 1992;2017(63):242–7.en
dcterms.referencesNazzal C, Frenz P, Alonso FT, Lanas F. Effective universal health coverage and improved 1-year survival after acute myocardial infarction: the Chilean experience. Health Policy Plan. 2016;31:700–5.en
dcterms.referencesBi Y, Gao R, Patel A, et al. Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study. Am Heart J. 2009;157: 509–16.en
dcterms.referencesHao Y, Liu J, Liu J, et al. Sex differences in in-hospital management and outcomes of patients with acute coronary syndrome. Circulation. 2019;139: 1776–85.en
dcterms.referencesLi M, Huang Y, Du X, et al. Impact of prior use of four preventive medications on outcomes in patients hospitalized for acute coronary syndrome—results from CPACS-2 Study. PLoS One. 2016;11:e0163068.en
dcterms.referencesSun YJ, Li YZ, Jiang DM, et al. Relationship between low-density lipoprotein levels on admission and 1-year outcome in patients with acute ST-segmentelevation myocardial infarction. Kaohsiung J Med Sci. 2013;29:206–13.en
dcterms.referencesTian L, Yang Y, Zhu J, et al. Impact of previous stroke on short-term myocardial reinfarction in patients with acute ST segment elevation myocardial infarction: an observational multicenter study. Medicine. 2016;95:e2742.en
dcterms.referencesWang Y, Cong H, Lu C, Liu J, Wu J. Use of secondary prevention medications among patients with acute coronary syndromes in Tianjin, China. Value Health. 2017;20:A276–7.en
dcterms.referencesPoh KK, Ambegaonkar B, Baxter CA, et al. Lowdensity lipoprotein cholesterol target attainment in patients with stable or acute coronary heart disease in the Asia-Pacific region: results from the Dyslipidemia International Study II. Eur J Prev Cardiol. 2018;25:1950–63.en
dcterms.referencesSiddiqui A, Toaima K, Fakher M, Hamed L, Siddiqui T. Assessment of hospital performance using quality of care indicators in patients with acute ST elevation myocardial infarction (AQcare-STEMI). Eur Heart J Acute Cardiovasc Care. 2018;7:226.en
dcterms.referencesAl-Rasadi K, Al-Zakwani I, Zubaid M, et al. Prevalence, predictors, and impact of low high-density lipoprotein cholesterol on in-hospital outcomes among acute coronary syndrome patients in the Middle East. Open Cardiovasc Med J. 2011;5:203–9.en
dcterms.referencesAl-Jarallah M, Al-Mallah MH, Zubaid M, et al. Trends in the use of evidence-based therapies early in the course of acute myocardial infarction and its influence on short term patient outcomes. Open Cardiovasc Med J. 2011;5:171–8.en
dcterms.referencesAl Saleh AS, Alhabib KF, Alsheik-Ali AA, et al. Predictors and impact of in-hospital recurrent myocardial infarction in patients with acute coronary syndrome: findings from Gulf RACE-2. Angiology. 2017;68:508–12.en
dcterms.referencesShehab A, Al-Dabbagh B, AlHabib KF, et al. Gender disparities in the presentation, management and outcomes of acute coronary syndrome patients: data from the 2nd Gulf Registry of Acute Coronary Events (Gulf RACE-2). PLoS One. 2013;8:e55508.en
dcterms.referencesEl-Hajj MS, Saad A, Al-Suwaidi J. Utilization of evidence-based secondary prevention medications at the time of discharge in patients with acute coronary syndrome (ACS) in Qatar. Curr Vasc Pharmacol. 2016;14:394–403.en
dcterms.referencesNaeem KB, Abdulrazzaq N. Demographics of acute myocardial infarction: experience at a non-PCI (percutaneous coronary intervention) center in Middle East. Eur Heart J Acute Cardiovasc Care. 2018;7:241.en
dcterms.referencesAl-Zakwani I, Zubaid M, Alsheikh-Ali AA, Almahmeed W, Rashed W. Effect of evidence-based cardiac drug therapy on mortality in patients with acute coronary syndrome: findings from the Gulf COAST registry. Cardiovasc Ther. 2018;36:e12463.en
dcterms.referencesBanerjee S, Kumar V, Ramachandran P, Kamath A. Does the pharmacological management of unstable angina vary with age and gender—a descriptive study. J Clin Diagn Res. 2010;4:3150–7.en
dcterms.referencesDilip C, Cholamugath S, Baby M, Pattani D. Prevalence of cardiovascular risk factors and management practices of acute coronary syndrome in a tertiary care hospital. J Basic Clin Physiol Pharmacol. 2015;26:547–54.en
dcterms.referencesMohanan PP, Mathew R, Harikrishnan S, et al. Presentation, management, and outcomes of 25,748 acute coronary syndrome admissions in Kerala, India: results from the Kerala ACS Registry. Eur Heart J. 2013;34:121–9.en
dcterms.referencesPagidipati NJ, Huffman MD, Jeemon P, et al. Association between gender, process of care measures, and outcomes in ACS in India: results from the detection and management of coronary heart disease (DEMAT) registry. PLoS One. 2013;8:e62061.en
dcterms.referencesSharma KK, Mathur M, Lodha S, et al. Study of differences in presentation, risk factors and management in diabetic and nondiabetic patients with acute coronary syndrome. Indian J Endocrinol Metab. 2016;20:354–8.en
dcterms.referencesHammer Y, Iakobishvili Z, Hasdai D, et al. Guideline-recommended therapies and clinical outcomes according to the risk for recurrent cardiovascular events after an acute coronary syndrome. J Am Heart Assoc. 2018;7:e009885.en
dcterms.referencesKopel E, Klempfner R, Goldenberg I, Schwammenthal E. Estimating mortality in survivors of the acute coronary syndrome by the 4-drug score. Cardiology. 2014;127:83–9.en
dcterms.referencesErlikh AD. Evolution of acute coronary syndrome treatment during last years in Russian hospitals (based on results of RECORDS registries). Circulation. 2017;10:A162.en
dcterms.referencesGriffiths B, Lesosky M, Ntsekhe M. Self-reported use of evidence-based medicine and smoking cessation 6–9 months after acute coronary syndrome: a single-centre perspective. S Afr Med J. 2014;104:483–7.en
dcterms.referencesLee CH, Fang CC, Tsai LM, et al. Patterns of acute myocardial infarction in Taiwan from 2009 to 2015. Am J Cardiol. 2018;122:1996–2004.en
dcterms.referencesCheng CC, Huang WC, Chiou KR. Body mass index and outcome of acute myocardial infarction—is there an obesity paradox? Acta Cardiol Sin. 2013;29: 413–20.en
dcterms.referencesNguyen T, Le KK, Cao HTK, et al. Association between in-hospital guideline adherence and postdischarge major adverse outcomes of patients with acute coronary syndrome in Vietnam: a prospective cohort study. BMJ Open. 2017;7:e017008.en
dcterms.referencesNguyen T, Nguyen TH, Pham HT, et al. Physicians’ adherence to acute coronary syndrome prescribing guidelines in Vietnamese hospital practice: a crosssectional study. Trop Med Int Health. 2015;20: 627–37.en
oaire.versioninfo:eu-repo/semantics/publishedVersionen

Archivos

Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
381 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca